The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis
Objective. Recent studies have demonstrated that enteric glial cells (EGC) participate in the homeostasis of the gastrointestinal tract. This study investigated whether enteroglial markers, including S100B protein and glial fibrillary acidic protein (GFAP), can serve as noninvasive indicators of EGC...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2014/986525 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559835439169536 |
|---|---|
| author | Asuman Celikbilek Mehmet Celikbilek Seda Sabah Nermin Tanık Elif Borekci Serkan Dogan Yavuz Akin Suleyman Baldane Kemal Deniz Neziha Yilmaz Omer Ozbakir Mehmet Yucesoy |
| author_facet | Asuman Celikbilek Mehmet Celikbilek Seda Sabah Nermin Tanık Elif Borekci Serkan Dogan Yavuz Akin Suleyman Baldane Kemal Deniz Neziha Yilmaz Omer Ozbakir Mehmet Yucesoy |
| author_sort | Asuman Celikbilek |
| collection | DOAJ |
| description | Objective. Recent studies have demonstrated that enteric glial cells (EGC) participate in the homeostasis of the gastrointestinal tract. This study investigated whether enteroglial markers, including S100B protein and glial fibrillary acidic protein (GFAP), can serve as noninvasive indicators of EGC activation and disease activity in UC patients.
Methods. This clinical prospective study included 35 patients with UC and 40 age- and sex-matched controls. The diagnosis of UC was based on standard clinical, radiological, endoscopic, and histological criteria. Clinical disease activity was evaluated using the Modified Truelove-Witts Severity Index. Serum samples were analyzed for human GFAP and S100B using commercial enzyme-linked immunosorbent assay kits. Results. GFAP was not detected in the serum of either UC patients or controls
(P>0.05). However, we found a significant (P<0.001) decrease in the serum S100B levels in the UC patients. No correlation between the serum S100B level and the disease activity or duration was observed
(P>0.05). The serum S100B levels did not differ between UC patients with active disease (24 patients, 68.6%) or in remission (11 patients, 31.4%)
(P>0.05). Conclusions. Ulcerative colitis patients had significantly lower serum S100B levels, while GFAP was of no diagnostic value in UC patients. |
| format | Article |
| id | doaj-art-65a0581d8ad143bfadbadf616743827d |
| institution | Kabale University |
| issn | 2090-8040 2042-0099 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Inflammation |
| spelling | doaj-art-65a0581d8ad143bfadbadf616743827d2025-02-03T01:29:03ZengWileyInternational Journal of Inflammation2090-80402042-00992014-01-01201410.1155/2014/986525986525The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative ColitisAsuman Celikbilek0Mehmet Celikbilek1Seda Sabah2Nermin Tanık3Elif Borekci4Serkan Dogan5Yavuz Akin6Suleyman Baldane7Kemal Deniz8Neziha Yilmaz9Omer Ozbakir10Mehmet Yucesoy11Department of Neurology, Medical School, Bozok University, 66200 Yozgat, TurkeyDepartment of Gastroenterology, Medical School, Bozok University, 66200 Yozgat, TurkeyDepartment of Medical Biology, Medical School, Bozok University, 66200 Yozgat, TurkeyDepartment of Neurology, Medical School, Bozok University, 66200 Yozgat, TurkeyDepartment of Internal Medicine, Medical School, Bozok University, 66200 Yozgat, TurkeyDepartment of Gastroenterology, Medical School, Erciyes University, 38039 Kayseri, TurkeyDepartment of Internal Medicine, Medical School, Erciyes University, 38039 Kayseri, TurkeyDepartment of Internal Medicine, Medical School, Erciyes University, 38039 Kayseri, TurkeyDepartment of Pathology, Medical School, Erciyes University, 38039 Kayseri, TurkeyDepartment of Infectious Diseases and Microbiology, Medical School, Bozok University, 66200 Yozgat, TurkeyDepartment of Gastroenterology, Medical School, Erciyes University, 38039 Kayseri, TurkeyDepartment of Gastroenterology, Medical School, Erciyes University, 38039 Kayseri, TurkeyObjective. Recent studies have demonstrated that enteric glial cells (EGC) participate in the homeostasis of the gastrointestinal tract. This study investigated whether enteroglial markers, including S100B protein and glial fibrillary acidic protein (GFAP), can serve as noninvasive indicators of EGC activation and disease activity in UC patients. Methods. This clinical prospective study included 35 patients with UC and 40 age- and sex-matched controls. The diagnosis of UC was based on standard clinical, radiological, endoscopic, and histological criteria. Clinical disease activity was evaluated using the Modified Truelove-Witts Severity Index. Serum samples were analyzed for human GFAP and S100B using commercial enzyme-linked immunosorbent assay kits. Results. GFAP was not detected in the serum of either UC patients or controls (P>0.05). However, we found a significant (P<0.001) decrease in the serum S100B levels in the UC patients. No correlation between the serum S100B level and the disease activity or duration was observed (P>0.05). The serum S100B levels did not differ between UC patients with active disease (24 patients, 68.6%) or in remission (11 patients, 31.4%) (P>0.05). Conclusions. Ulcerative colitis patients had significantly lower serum S100B levels, while GFAP was of no diagnostic value in UC patients.http://dx.doi.org/10.1155/2014/986525 |
| spellingShingle | Asuman Celikbilek Mehmet Celikbilek Seda Sabah Nermin Tanık Elif Borekci Serkan Dogan Yavuz Akin Suleyman Baldane Kemal Deniz Neziha Yilmaz Omer Ozbakir Mehmet Yucesoy The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis International Journal of Inflammation |
| title | The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis |
| title_full | The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis |
| title_fullStr | The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis |
| title_full_unstemmed | The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis |
| title_short | The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis |
| title_sort | serum s100b level as a biomarker of enteroglial activation in patients with ulcerative colitis |
| url | http://dx.doi.org/10.1155/2014/986525 |
| work_keys_str_mv | AT asumancelikbilek theserums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT mehmetcelikbilek theserums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT sedasabah theserums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT nermintanık theserums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT elifborekci theserums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT serkandogan theserums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT yavuzakin theserums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT suleymanbaldane theserums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT kemaldeniz theserums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT nezihayilmaz theserums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT omerozbakir theserums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT mehmetyucesoy theserums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT asumancelikbilek serums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT mehmetcelikbilek serums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT sedasabah serums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT nermintanık serums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT elifborekci serums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT serkandogan serums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT yavuzakin serums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT suleymanbaldane serums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT kemaldeniz serums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT nezihayilmaz serums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT omerozbakir serums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis AT mehmetyucesoy serums100blevelasabiomarkerofenteroglialactivationinpatientswithulcerativecolitis |